Tripos Discovery Research has promoted Mark Allen to senior vice president and managing director. Allen succeeds Peter Hecht, who will become CEO of Oridis Biomed, but will remain a Tripos scientific advisor. Allen was previously head of drug discovery support for Novartis Pharma UK, where he was head of drug discovery support. Prior to that position, Allen worked at CIBA-Geigy Pharma UK, and was eventually appointed head of core drug technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.